Bioavailability challenges associated with development of saponins as therapeutic and chemopreventive agents

Current Drug Targets

Volumn 13, Issue 14, 2012, Pages 1885-1899

  Gao, Song ^a   Basu, Sumit ^a   Yang, Zhen ^a   Deb, Arijita ^b   Hu, Ming ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b JADAVPUR UNIVERSITY   (India)

Author keywords

Bioavailability; Chemoprevention; Disposition; Intestinal; Saponins

Indexed keywords

ASTRAGALOSIDE IV; BREAST CANCER RESISTANCE PROTEIN; DIGOXIN; DIOSCIN; DIOSGENIN; ELACRIDAR; GINSENOSIDE RB 1; GINSENOSIDE RF; GINSENOSIDE RG 1; GINSENOSIDE RG 3; GINSENOSIDE RH 2; GINSENOSIDE RH1; GLYCYRRHIZIC ACID; MULTIDRUG RESISTANCE PROTEIN; OLEANOLIC ACID; PANTOPRAZOLE; PEPTIDE TRANSPORTER 1; PROBENECID; SAIKOSAPONIN A; SAPONIN; SODIUM GLUCOSE COTRANSPORTER; TARIQUIDAR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; ZOSUQUIDAR;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DEGLYCOSYLATION; DEHYDRATION; DIFFUSION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STABILITY; DRUG SULFATION; ETHERIFICATION; FATIGUE; GASTROINTESTINAL ABSORPTION; HEADACHE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYDROLYSIS; HYDROPHOBICITY; HYPOTENSION; LIPOPHILICITY; NONHUMAN; OXIDATION; PAIN; PERMEABILITY; PHYSICAL CHEMISTRY; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; CHEMOPREVENTION; DRUG DISCOVERY; HUMANS; INTESTINAL ABSORPTION; NEOPLASMS; SAPONINS;

EID: 84876751379     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012804545498     Document Type: Review

References (139)

1. Melzig MF, Bader G, Loose R. Investigations of the mechanisms of membrane activity of selected triterpenoid saponins. Planta Med 2001; 67: 43-48.
2. Sparg SG, Light ME, van Staden J. Biological activities and distribution of plant saponins. J Ethnopharmacol 2004; 94: 219-43.
3. Xu FQ, Zhong HM, Liu HY, Chen CX. Steroidal saponins from Lysimachia Paridiformis. J Asian Nat Prod Res 2007; 9: 493-7.
4. Fiore C, Eisenhut M, Ragazzi E, Zanchin G, Armanini D. A history of the therapeutic use of liquorice in Europe. J Ethnopharmacol 2005; 99: 317-24.
5. Sun HX, Xie Y, Ye YP. Advances in saponin-based adjuvants. Vaccine 2009; 27: 1787-96.
6. Zhang Z, Li S. Cytotoxic triterpenoid saponins from the fruits of Aesculus pavia L. Phytochemistry 2007; 67: 784-94.
7. Qi LW, Wang CZ, Yuan CS. American ginseng: potential structure-function relationship in cancer chemoprevention. Biochem Pharmacol 2010; 80: 947-54.
8. Raju J, Mehta R. Cancer chemopreventive and therapeutic effects of diosgenin, a food saponin. Nutr Cancer 2009; 61: 27-35.
9. Man S, Gao W, Zhang Y, Huang L, Liu C. Chemical study and medical application of saponins as anti-cancer agents. Fitoterapia 2010; 81: 703-14.
10. Dzubak P, Hajduch M, Vydra D, et al. Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat Prod Rep 2006; 23: 394-411.
11. Kuo RY, Qian K, Morris-Natschke SL, Lee KX. Plant-derived triterpenoids and analogues as antitumor and anti-HIV agents. Nat Prod Rep 2009; 26: 1321-44.
12. Patlolla, JM, Rao CV. Triterpenoids for cancer prevention and treatment: current status and future prospects. Curr Pharm Biotechnol 2012; 13: 147-55.
13. Petronelli A, Pannitteri G, Testa U. Triterpenoids as new promising anticancer drugs. Anticancer Drugs 2009; 20: 880-92.
14. Rao AV, Sung MK. Saponins as anticarcinogens. J Nutr 1995; 125: 717S-24S.
15. Rafat M, Fong KW, Goldsipe A, et al. Association (micellization) and partitioning of aglycon triterpenoids. J Colloid Interface Sci 2008; 325: 324-30.
16. Connolly JD, Hill RA. Triterpenoids. Nat Prod Rep 2010; 27: 79-132.
17. Connolly JD, Hill RA. Triterpenoids. Nat Prod Rep 2008; 25: 794-830.
18. Hill RA, Connolly JD. Triterpenoids. Nat Prod Rep 2011; 28: 1087-117
19. Hill RA, Connolly JD. Triterpenoids. Nat Prod Rep 2012; 29: 780-818.
20. Friess SL, Standaert FG, Whitcomb ER, et al. Some pharmacologic properties of holothurin A, a glycosidic mixture from the sea cucumber. Ann N Y Acad Sci 1960; 90:893-901.
21. Büchele B, Simmet T. Analysis of 12 different pentacyclic triterpenic acids from frankincense in human plasma by highperformance liquid chromatography and photodiode array detection. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 795: 355-62.
22. Kaunzinger A, Baumeister A, Cuda K, et al. Determination of 11- keto-boswellic acid in human plasma. J Pharm Biomed Anal 2002; 28: 729-39.
23. Sharma S, Thawani V, Hingorani L, Shrivastava M, Bhate VR, Khiyani R. Pharmacokinetic study of 11-Keto beta-Boswellic acid. Phytomedicine 2004; 11: 255-60.
24. Zhen Y, Song G, Wang J, Taijun Y, Ming Y, Ming H. Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. Drug Metab Dispos 2011; 39: 1866-72.
25. Gu Y, Wang GJ, Sun JG, et al. Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogs. Food Chem Toxicol 2009; 47: 2257-68.
26. Thomas VH, Bhattachar S, Hitchingham L, Philip Z. The road map to oral bioavailability: an industrial perspective. Expert Opin Drug Metab Toxicol 2006; 2: 591-608.
27. Sato K, Mochizuki M, Saiki I, Yoo YC, Samukawa K, Azuma I. Inhibition of tumor angiogenesis and metastasis by a saponin of Panax ginseng, ginsenoside-Rb2. Biol Pharm Bull 1994; 17:635-9.
28. Shibata S. Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds. J Korean Med Sci 2001; 16 Suppl: S28-S37.
29. Li K, Chen X, Xu J. Liquid chromatography/tandem mass spectrometry for pharmacokinetic studies of 20(R)-ginsenoside Rg3 in dog. Rapid Commun Mass Spectrom 2005; 19: 813-7.
30. Pang H, Wang HL, Fu L, Su CY. Pharmacokinetic studies of 20(R)-ginsenoside RG3 in human volunteers. Yao Xue Xue Bao 2001; 36: 170-3.
31. Jiang JW, Chen XM, Chen XH, Zhang SS. Ginsenoside Rg3 inhibit hepatocellular carcinoma growth via intrinsic apoptotic pathway. World J Gastroenterol 2011; 17: 3605-13.
32. Pan XY, Guo H, Han J, et al. Ginsenoside Rg3 attenuates cell migration via inhibition of aquaporin 1 expression in PC-3M prostate cancer cells. Eur J Pharmacol 2012; 683: 27-34.
33. Zhang C, Liu L, Yu Y, Che B. Tang J, Li X. Antitumor effects of ginsenoside Rg3 on human hepatocellular carcinoma cells. Mol Med Report 2012; 5: 1295-8.
34. Qian T, Cai Z, Wong RN, Jiang ZH. Liquid chromatography/mass spectrometric analysis of rat samples for in vivo metabolism and pharmacokinetic studies of ginsenoside Rh2. Rapid Commun Mass Spectrom 2005; 19: 3549-54.
35. Xie HT, Wang GJ, Lv H, et al. Development of a HPLC-MS assay for ginsenoside Rh2, a new anti-tumor substance from natural product and its pharacokinetic study in dogs. Eur J Drug Metab Pharmacokinet 2005; 30: 63-7.
36. Asl, MN, Hosseinzadeh H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res 2008; 22: 709-24.
37. Kuttan, G, Pratheeshkumar P, Manu KA, et al. Inhibition of tumor progression by naturally occurring terpenoids. Pharm Biol 2011; 49: 995-1007.
38. Lee CK, Park KK, Lim SS, Park JH, Chuang WY. Effects of the licorice extract against tumor growth and cisplatin-induced toxicity in a mouse xenograft model of colon cancer. Biol Pharm Bull 2007; 30: 2191-5.
39. Wang ZY, Nixon DW. Licorice and cancer. Nutr Cancer 2001; 39: 1-11.
40. Ren W, Lu Y, Jing J, et al. Determination of glycyrrhizin in dog plasma by liquid chromatography-mass spectrometry and its application in pharmacokinetic studies. Eur J Mass Spectrom (Chichester, Eng) 2010; 16: 673-8.
41. Tanaka N, Yamamura Y, Santa T, et al. Pharmacokinetic profiles of glycyrrhizin in patients with chronic hepatitis. Biopharm Drug Dispos 1993; 14: 609-14.
42. Fujiwara, K, Ogihara Y. Pharmacological effects of oral saikosa ponin a may differ depending on conditions of the gastrointestinal tract. Life Sci 1986; 39: 297-301.
43. Kim BM, Hong SH. Sequential caspase-2 and caspase-8 activation is essential for saikosaponin a-induced apoptosis of human colon carcinoma cell lines. Apoptosis 2011; 16: 184-97.
44. Sun Y, Cai TT, Zhou XB, Xu Q. Saikosaponin a inhibits the proliferation and activation of T cells through cell cycle arrest and induction of apoptosis. Int Immunopharmacol 2009; 9: 978-83.
45. Qi H, Wei L, Han Y, Zhang Q, Lau AS, Rong J. Proteomic characterization of the cellular response to chemopreventive triterpenoid astragaloside IV in human hepatocellular carcinoma cell line HepG2. Int J Oncol 2010; 36: 725-35.
46. Li K, Tang Y, Fawcett JP, Zhong D. Characterization of the pharmacokinetics of dioscin in rat. Steroids 2005; 70: 525-30.
47. Xu QF, Fang XL, Chen DF. Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. J Ethnopharmacol 2003; 84: 187-92.
48. Ren HC, Sun JG, Wang GJ. Sensitive determination of 20(S)- protopanaxadiol in rat plasma using HPLC-APCI-MS: application of pharmacokinetic study in rats. J Pharm Biomed Anal 2008; 48: 1476-80.
49. Yamamura Y, Santa T, Kotaki H, Uchino K, Sawada Y, Iga T. Administration-route dependency of absorption of glycyrrhizin in rats: intraperitoneal administration dramatically enhanced bioavaila bility. Biol Pharm Bull 1995; 18: 337-41.
50. Yu K, Chen F, Li C. Absorption, disposition, and pharmacokinetics of saponins from Chinese medicinal herbs: what do we know and what do we need to know more? Curr Drug Metab 2012; 13: 577-98.
51. Edward H. Kerns, Li D. Drug-like Properties: Concepts, Structure Design and Methods for ADME to Toxicity Optimization, 2nd ed, San Diago, Elsevier Inc:,2008; pp 56.
52. Jager S, Winkler K, Pfuller U, et al. Solubility studies of oleanolic acid and betulinic acid in aqueous solutions and plant extracts of Viscum album L. Planta Med 2007; 73: 157-62.
53. Koga K, Kawashima S, Shibata N, Takada K, Murakami M. Preparation and rectal absorption of highly concentrated glycyrrhizin solution. Biol Pharm Bull 2003; 26: 1299-305.
54. Zhao J, Yang CH, Hu M, Liu ZQ. Absorption characteristics of ginsenoside Rb2 in Caco-2 cell monolayer. Nan Fang Yi Ke Da Xue Xue Bao 2009; 29: 2387-90.
55. Xiong J, Guo J, Huang L, et al. Self-micelle formation and the incorporation of lipid in the formulation affect the intestinal absorption of Panax notoginseng. Int J Pharm 2008; 360: 191-6.
56. Yamanaka T, Vincken JP, de Waard P, Sanders M, Takada N, Gruppen H. Isolation, characterization, and surfactant properties of the major triterpenoid glycosides from unripe tomato fruits. J Agric Food Chem 2008; 56: 11432-40.
57. Song G, Ming H. Bioavailability challenges associated with development of anti-cancer phenolics. Mini Rev Med Chem 2010; 10: 550-67.
58. Hostettmann K, Maston A. Saponins. Cambridge Cambridge University Press, 1995
59. Waller GR, Kazuo Y. Saponin used in food and agriculture. New York, Plenum Press, 1995.
60. Yoshiki Y, Kudou S, Okubo K. Relationship between chemical structures and biological activities of triterpenoid saponins from soybean. Biosci Biotechnol Biochem 1998; 62: 2291-9.
61. Qian T, Jiang ZH, Cai Z. High-performance liquid chromatography coupled with tandem mass spectrometry applied for metabolic study of ginsenoside Rb1 on rat. Anal Biochem 2006; 352: 87-96.
62. Kang KS, Kim HY, Yamabe N, Yokozawa T. Stereospecificity in hydroxyl radical scavenging activities of four ginsenosides produced by heat processing. Bioorg Med Chem Lett 2006; 16: 5028-31.
63. Lee SM, Shon HJ, Choi CS. Ginsenosides from heat processed ginseng. Chem Pharm Bull (Tokyo) 2009; 57: 92-4.
64. Park IH, Kim NY, Han SB, et al. Three new dammarane glycosides from heat processed ginseng. Arch Pharm Res 2002; 25: 428-32.
65. Fasano M, Curry S, Terreno E, et al. The extraordinary ligand binding properties of human serum albumin. IUBMB Life 2005; 57: 787-96.
66. Toutain PL, Bousquet-Mélou A. Volumes of distribution. J Vet Pharmacol Ther 2004; 27: 441-53.
67. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002; 71: 115-21.
68. Han M, Fu S, Fang XL. Comparison between the characteristics of absorption and pharmacokinetic behavior of ginsenoside Rg1 and ginsenoside Rb, of Panax notoginseng saponins. Yao Xue Xue Bao 2007; 42: 849-53.
69. Koga K, Tomoyama M, Ohyanagi K, Takada K. Pharmacokinetics of glycyrrhizin in normal and albumin-deficient rats. Biopharm Drug Dispos 2008; 29: 373-81.
70. Amidon, GL, Lee PI, Topp EM, Yu LX. Analytical Solutions to Mass Transfer. in Transport processes in pharmaceutical systems. Dekker, New York. 2000, pp 23-54
71. Faller B, Artificial membrane assays to assess permeability. Curr Drug Metab 2008; 9: 886-92.
72. Liu H, Yang J, Du F, et al. Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats. Drug Metab Dispos 2009; 37: 2290-8.
73. Ming H, Xingling L. Oral bioavailability Oral bioavailability: basic principles, advanced concepts, and applications. New York, John Wiley & Sons, 2011.
74. Lee HU, Bae EA, Han MJ, Kim NJ, Kim DH. Hepatoprotective effect of ginsenoside Rb1 and compound K on tert-butyl hydroperoxide-induced liver injury. Liver Int 2005; 25: 1069-73.
75. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175: 880-5.
76. Xie HT, Wang GJ, Chen M, http://www.ncbi.nlm.nih.gov/pubmed?term=JiangXL%5BAuthor%5D&cauthor= true&author_uid=15684507etal. Uptake and metabolism of ginsenoside Rh2 and its aglycon protopanaxadiol by Caco-2 cells. Biol Pharm Bull 2005; 28: 383-6.
77. B Brand W, van der Wel PA, Rein MJ, et al. Metabolism and transport of the citrus flavonoid hesperetin in Caco-2 cell monolayers. Drug Metab Dispos 2008; 36: 1794-802.
78. Alvarez AI, Real R, Pérez M, Mendoza G, Prieto JG, Merino G. Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. J Pharm Sci 2010, 99: 598-617.
79. Murakami T, Takano M, Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol 2008; 4: 923-39.
80. Zhang J, Zhou F, Niu F, Lu M, Wu X, Sun J, Wang G. Stereoselective regulations of P-glycoprotein by ginsenoside Rh2 epimers and the potential mechanisms from the view of pharmacokinetics. PLoS One 2012; 7: e35768.
81. Hirabayashi H, Sugimoto H, Matsumoto S. Development of a quantification method for digoxin, a typical P-glycoprotein probe in clinical and non-clinical studies, using high performance liquid chromatography-tandem mass spectrometry: the usefulness of negative ionization mode to avoid competitive adduct-ion formation. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 3837-44.
82. Mease K, Sane R, Podila L, Taub ME. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. J Pharm Sci 2012; 101: 1888-97.
83. Yang Z, Wang JR, Niu T, et al. Inhibition of p-glycoprotein leads to improved oral bioavailability of compound k, an anticancer metabolite of red ginseng extract produced by gut microflora. Drug Metab Dispos 2012; 40: 1538-44.
84. Han M, Sha X, Wu Y, Fang X. Oral absorption of ginsenoside Rb1 using in vitro and in vivo models. Planta Med 2006; 72: 398-404.
85. Nishimura, N. Effects of Chinese herbal medicines on intestinal drug absorption. Yakugaku Zasshi 2005; 125: 363-9.
86. Yan M, Li L, Li H, Fang P, Xu P, Zheng M, Xu D. Effect of 18alpha-glycyrrhizic acid and 18beta-glycyrrhizic acid on P-gp function and expression in Caco-2 cells. Zhongguo Zhong Yao Za Zhi 2012; 37: 99-103.
87. Choi CH, Kang G, Mi YD. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. Planta Med 2003; 69: 235-40
88. Doligalska M, Jóźwicka K, Kiersnowska M, Mroczek A, Paczkowski C, Janiszowska W. saponins affect the function of Pglycoprotein and reduce the survival of the free-living stages of Heligmosomoides bakeri. Vet Parasitol 2011; 179: 144-51.
89. Kim SW, Kwon HY, Chi DW, et al. Reversal of P-glycoproteinmediated multidrug resistance by ginsenoside Rg(3). Biochem Pharmacol 2003; 65: 75-82.
90. Pokharel YR, Kim ND, Han HK, Oh WK, Kang KW. Increased ubiquitination of multidrug resistance 1 by ginsenoside Rd. Nutr Cancer 2010; 62: 252-9.
91. Zhang J, Zhou F, Wu X, et al. 20(S)-ginsenoside Rh2 noncompe titively inhibits P-glycoprotein in vitro and in vivo: a case for herbdrug interactions. Drug Metab Dispos 2010; 38: 2179-87.
92. Zhou Y, Li W, Chen L, Ma S, Ping L, Yang Z. Enhancement of intestinal absorption of akebia saponin D by borneol and probenecid in situ and in vitro. Environ Toxicol Pharmacol 2010; 29: 229-34.
93. Xiong J, Sun M, Guo J, Huang L, et al. Active absorption of ginsenoside Rg1 in vitro and in vivo: the role of sodium-dependent glucose co-transporter 1. J Pharm Pharmacol 2009; 61: 381-6.
94. Han M, Fang XL. Difference in oral absorption of ginsenoside Rg1 between in vitro and in vivo models. Acta Pharmacol Sin 2006; 27: 499-505.
95. Han M, Han LM, Wang QS, et al. Mechanism of oral absorption of panaxnotoginseng saponins. Yao Xue Xue Bao 2006; 41: 498-505.
96. Meng Z, Zhang H, Zhao Y, Lan D, Ji L. Transport behavior and efflux of Rg1 in rat pulmonary epithelial cells. Biomed Chromatogr 2007; 21: 635-41.
97. Hao HP, Lai L, Zheng C, Wang Q. Microsomal cytochrome P450 mediated metabolism of protopanaxatriol ginsenosides: metabolites profile, reaction phenotyping, and structure metabolism relation ship. Drug Metab Dispos 2010; 38: 1731-9.
98. Yang L, Deng Y, Xu S, Zeng X. In vivo pharmacokinetic and metabolism studies of ginsenoside Rd. J. Chromatogr. B 2007; 854: 77-84.
99. Gu Y, Wang GJ, Sun JG, et al. Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng in rats and dogs. Food Chem. Toxicol,2009; 47: 2257-68.
100. Qian T, Cai Z, Wong RN, Mak NK, Jiang ZH. In vivo rat metabolism and pharmacokinetic studies of ginsenoside Rg3. J. Chromatogr. B 2005; 816: 223-32.
101. Kasai R, Hara K, Dokan R, et al. Major metabolites of ginseng sapogenins formed by rat liver microsomes. Chem. Pharm. Bull.,2000; 48: 1226-7.
102. Hasler F, Krapf R, Brenneisen R, Bourquin D, Krähenbühl S. Determination of 18 β-glycyrrhetinic acid in biological fluids from humans and rats by solid-phase extraction and high-performance liquid chromatography. J. Chromatogr. 1993; 620: 73-82.
103. Iveson P, Lindup WE, Parke DV, Williams RT. The metabolism of carbenoxolone in the rat. Xenobiotica 1971; 1: 79-95.
104. Jing J, Ren W, Chen X, et al. Glucuronide-sulfate diconjugate as a novel metabolite of glycyrrhetic acid in rat bile. Drug Metab Pharmacokinet 2008; 23: 175-80.
105. Parke DV, Pollock S, Williams RT. The fate of tritiumlabelled β- glycyrrhetic acid in the rat. J Pharm Pharmacol,1963; 15: 500-6.
106. Yamamura Y, Kawakami J, Santa T, et al. Selective highperformance liquid chromatographic method for the determination of glycyrrhizin and glycyrrhetic acid-3-O-glucuronide in biological fluids: application of ionpair extraction and fluorescence labelling agent. J Chromatogr 1991; 567: 151-60.
107. Akao T, Akao T, Hattori M, et al. Hydrolysis of glycyrrhizin to 18- glycyrrhetyl monoglucuronide by lysosomal beta-D-glucuronidase of animal livers. Biochem Pharmacol 1991; 41: 1025-9.
108. Lu Y, Zhu J, Chen X, et al. Identification of human UDPglucuronosyltransferase isoforms responsible for the glucuroni dation of glycyrrhetinic acid. Drug Metab. Pharmacokinet 2009; 24: 523-8.
109. Berg RD. The indigenous gastrointestinal microflora. Trends Microbiol 1996; 4: 430-5.
110. Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol 1977; 31: 107-33.
111. Salminen S, Benno Y, de Vos W. Intestinal colonisation, microbiota and future probiotics? Asia Pac J Clin Nutr 2006; 15: 558-62.
112. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science 2001; 292: 1115-8.
113. Quan LH, Min JW, Jin Y, Wang C, Kim YJ, Yang DC. Enzymatic biotransformation of ginsenoside Rb1 to compound K by recombi nant beta-glucosidase from Microbacterium esteraromaticum. J Agric Food Chem 2012; 60: 3776-81.
114. Wang CZ, Du GJ, Zhang Z. Ginsenoside compound K, not Rb1, possesses potential chemopreventive activities in human colorectal cancer. Int J Oncol 2012; 40: 1970-6.
115. Akao T, Kida H, Kanaoka M, Hattori M, Kobashi K. Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. J Pharm Pharmacol 1998; 50: 1155-60.
116. Bae EA, Choo MK, Park EK, Park SY, Shin HY, Kim DH. Metabolism of ginsenoside Rc by human intestinal bacteria and its related antiallergic activity. Biol Pharm Bull 2002; 25: 743-7.
117. Bae EA, Park SY, Kim DH. Constitutive -glucosidases hydrolyzing ginsenoside Rb1 and Rb2 from human intestinal bacteria. Biol Pharm Bull 2000; 23: 1481-5.
118. Bae EA, Shin JE, Kim DH. Metabolism of ginsenoside Re by human intestinal microflora and its estrogenic effect. Biol Pharm Bull 2005; 28: 1903-8.
119. Hasegawa H, Sung JH, Benno Y. Role of human intestinal Prevotella oris in hydrolyzing ginseng saponins. Planta Med 1997; 63: 436-40.
120. Hasegawa H, Sung JH, Matsumiya S, Uchiyama M. Main ginseng saponin metabolites formed by intestinal bacteria. Planta Med 1996; 62: 453-7.
121. Tawab MA, Bahr U, Karas M. Degradation of ginsenosides in humans after oral administration. Drug Metab Dispos 2003; 31: 1065-71.
122. Wang Y, Liu TH, Wang W, Wang BX. Research on the transformation of ginsenoside Rg1 by intestinal flora. Zhongguo Zhong Yao Za Zhi 2001; 26: 188-90.
123. Hattori M, Sakamoto T, Kobashi K, Namba T. Metabolism of glycyrrhizin by human intestinal flora., Planta Med.,1983; 48: 38-42.
124. Akao T, Akao T, Kobashi. Glycyrrhizin -D-glucuronidase of Eubacterium sp. from human intestinal flora. Chem Pharm Bull 1987; 35: 705-10.
125. Kim DH, Hong SW, Kim BT, Bae EA, Park HY, Han MJ. Biotransformation of glycyrrhizin by human intestinal bacteria and its relation to biological activities., Arch Pharm Res 2000; 23: 172-7.
126. Hattori M, Sakamoto T, Yamagishi T, et al. Metabolism of glycyrrhizin by human intestinal flora. 2. Isolation and charac terization of human intestinal bacteria capable of metabolizing glycyrrhizin and related compounds. Chem Pharm Bull 1985; 33: 210-7.
127. Ma HYZ, Qin L, Wang BX. Studies on the metabolism of DX by intestinal bacteria and the absorbed components in serum. China Pharm, 2002; 13: 204-5.
128. Shimizu K, Amagaya S, Ogihara Y. Structural transformation of saikosaponins by gastric juice and intestinal flora. J Pharmaco biodyn 1985; 8: 718-25.
129. Kida H, Akao T, Meselhy MR, Hattori M. Enzymes responsible for the metabolism of saikosaponins from Eubacterium sp. A- 44, a human intestinal anaerobe. Biol Pharm Bull 1997; 20: 1274-8.
130. Kida H, Akao T, Meselhy MR, Hattori M. Metabolism and pharmacokinetics of orally administered saikosaponin b1 in conventional, germ-free and Eubacterium sp. A-44-infected gnotobiote rats. Biol Pharm Bull 1998; 21: 588-93.
131. Cao F, Jia J, Yin Z, et al. Ethylene Glycol-Linked Amino Acid Diester Prodrugs of Oleanolic Acid for PepT1-Mediated Transport: Synthesis, Intestinal Permeability and Pharmacokinetics. Mol Pharm 2012.
132. Hao HZ, Chen TB, Jin MG, et al. Recent advance in solidification/stabilization technology for the remediation of heavy metals-contaminated soil. Ying Yong Sheng Tai Xue Bao 2011; 22: 816-24.
133. Dantzig AH, Law KL, Cao J, Starling JJ. Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. Curr Med Chem 2001; 8: 39-50.
134. Malingré MM, Beijnen JH, Rosing H, http://www.ncbi.nlm.nih.gov/pubmed?term=KoopmanFJ%5BAuthor%5D&cauthor=true&cauthor_uid=11139311etal. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 2001; 84: 42-7.
135. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 2003; 55: 425-61.
136. Holdgate A, Foo A. Adenosine versus intravenous calcium channel antagonists for the treatment of supraventricular tachycardia in adults, Cochrane Database Syst Rev. 2006 18; 4: CD005154.
137. He JX, Akao T, Nishino T, Tani T. The influence of commonly prescribed synthetic drugs for peptic ulcer on the pharmacokinetic fate of glycyrrhizin from Shaoyao-Gancao-tang. Biol Pharm Bull,2001; 24: 1395-9.
138. He JX, Akao T, Tani T. Repetitive administration of Shaoyao- Gancao-tang to rats restores the bioavailability of glycyrrhizin reduced by antibiotic treatment. J Pharm Pharmacol 2003; 55: 1569-75.
139. Krief S, Thoison O, Sévenet T, Wrangham RW, Lavaud C. Triterpenoid saponin anthranilates from Albizia grandibracteata leaves ingested by primates in Uganda. J Nat Prod 2005; 68: 897-903.